Actinium Pharmaceuticals
Open
$1.12
Prev. Close
$1.12
High
$1.12
Low
$1.11
Market Snapshot
$36.5M
-1.1
-1.27
37
Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel targeted therapies. The company is headquartered in New York City, New York and currently employs 37 full-time employees. The company went IPO on 2014-03-26. The firm is advancing its lead product candidate Actimab-A, a CD33 targeting therapeutic, as potential backbone therapy in acute myeloid leukemia (AML) and other myeloid malignancies leveraging the mutation agnostic alpha-emitter radioisotope payload Actinium-225 (Ac-225). The firm is engaged with the National Cancer Institute (NCI) under the Cooperative Research and Development Agreement (CRADA) for development of Actimab-A in AML and other myeloid malignancies. ATNM-400 is the Company's novel non-PSMA targeting Ac-225 radiotherapy for prostate cancer. Iomab-ACT, its conditioning candidate, is being developed to improve patient access and outcomes for potentially curative cell and gene therapies. Its Iomab-B program is an induction and conditioning agent prior to bone marrow transplant in patients with r/r AML, which it is seeking a potential strategic partner for the United States.
emptyResult
Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel targeted therapies. The company is headquartered in New York City, New York and currently employs 37 full-time employees. The company went IPO on 2014-03-26. The firm is advancing its lead product candidate Actimab-A, a CD33 targeting therapeutic, as potential backbone therapy in acute myeloid leukemia (AML) and other myeloid malignancies leveraging the mutation agnostic alpha-emitter radioisotope payload Actinium-225 (Ac-225). The firm is engaged with the National Cancer Institute (NCI) under the Cooperative Research and Development Agreement (CRADA) for development of Actimab-A in AML and other myeloid malignancies. ATNM-400 is the Company's novel non-PSMA targeting Ac-225 radiotherapy for prostate cancer. Iomab-ACT, its conditioning candidate, is being developed to improve patient access and outcomes for potentially curative cell and gene therapies. Its Iomab-B program is an induction and conditioning agent prior to bone marrow transplant in patients with r/r AML, which it is seeking a potential strategic partner for the United States.
Recently from Cashu
Actinium Pharmaceuticals to Showcase Innovative Cancer Treatments at AACR Annual Meeting 2026
Actinium Pharmaceuticals, Inc. is set to unveil new preclinical data for its promising radioconjugate ATNM-400 and its acute myeloid leukemia (AML) treatment, Actimab-A, at the upcoming American Assoc…
Actinium Pharmaceuticals' ATNM-400: Promising Targeted Therapy for Breast Cancer Treatment
Innovative Antibody Radioconjugate Shows Promise for Breast Cancer Treatment Actinium Pharmaceuticals, Inc. (NYSE American: ATNM), a leader in targeted radiotherapies, presents encouraging preclinical…
Actinium Pharmaceuticals Unveils Promising Data for ATNM-400 in Targeted Breast Cancer Radiotherapy
Actinium Pharmaceuticals Advances Targeted Radiotherapy with ATNM-400 Actinium Pharmaceuticals, Inc. stands at the forefront of targeted radiotherapy with its latest presentation of preclinical data f…
Actinium Pharmaceuticals' ATNM-400 Shows Promise in Targeting Triple-Negative Breast Cancer
Actinium Pharmaceuticals Advances Radiotherapy with Promising Preclinical Data for ATNM-400 Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) is on the brink of a significant breakthrough in breast…